AML
News
ESMO helps hematologists assess new cancer drugs
The group’s new study evaluation tool, the ESMO-MCBS:H, is aimed at helping doctors and others determine the benefit of new blood cancer therapies...
Conference Coverage
Multiprong strategy makes clinical trials less White
Only a small percentage of eligible patients participate in clinical trials in the first place, and very few come from racial and ethnic minority...
Conference Coverage
CBSM phone app eases anxiety, depression in cancer patients
Few patients with cancer have access to psycho-oncologic support.
News
Drugmakers are abandoning cheap generics, and now U.S. cancer patients can’t get meds
On Nov. 22, three FDA inspectors arrived at the sprawling Intas Pharmaceuticals plant south of Ahmedabad, India, and found hundreds of trash bags...
Conference Coverage
Gilteritinib maintenance reduces relapse in MRD+ AML
Despite not meeting its primary endpoint, a trial in mutated acute myeloid leukemia showed the benefit of gilteritinib maintenance in certain...
Conference Coverage
CMML: GM-CSF inhibitor lenzilumab shows early promise
The PREACH-M trial has yielded encouraging preliminary results in treating CMML, a rare, “insidious” leukemia that can transform into AML.
Conference Coverage
‘Best’ for most APL patients: Chemo-free regimen
A chemo-free treatment regimen significantly improves survival over chemotherapy in patients with a rare, virulent leukemia, but those 50 and...
News
Widespread carboplatin, cisplatin shortages: NCCN survey
Only 64% of centers said they are still able to continue treating all current patients receiving carboplatin.
Conference Coverage
ASCO honors Hagop Kantarjian, MD, for leukemia research
Noted Lebanese-American oncologist who leads the leukemia department at MD Anderson Cancer Center is to receive a top award at ASCO 2023.
News
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.